CR20200216A - Polimorfos y formas sòlidas de un compuesto de pirimidinilamino-pirazol y mèdtodos de producciòn - Google Patents
Polimorfos y formas sòlidas de un compuesto de pirimidinilamino-pirazol y mèdtodos de producciònInfo
- Publication number
- CR20200216A CR20200216A CR20200216A CR20200216A CR20200216A CR 20200216 A CR20200216 A CR 20200216A CR 20200216 A CR20200216 A CR 20200216A CR 20200216 A CR20200216 A CR 20200216A CR 20200216 A CR20200216 A CR 20200216A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pyrimidinylamino
- polymorphs
- production
- methods
- solid forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
<p>La presente descripción hace referencia a formas amorfas y polimórficas cristalinas de 2-metil2-(3-metil-4-(4-(metilamino)-5-(trifluorometil)pirimidin-2-ilamino)-1H-pirazol-1-il)propanonitrilo o solvatos, tautómeros y cocristales o sales farmacéuticamente aceptables de este, así como a procesos para su elaboración.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589276P | 2017-11-21 | 2017-11-21 | |
| PCT/US2018/062102 WO2019104086A1 (en) | 2017-11-21 | 2018-11-20 | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200216A true CR20200216A (es) | 2021-03-19 |
Family
ID=66631734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200216A CR20200216A (es) | 2017-11-21 | 2018-11-20 | Polimorfos y formas sòlidas de un compuesto de pirimidinilamino-pirazol y mèdtodos de producciòn |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10370361B2 (es) |
| EP (1) | EP3717473B1 (es) |
| JP (1) | JP7303821B2 (es) |
| KR (1) | KR20200089713A (es) |
| CN (1) | CN111819174A (es) |
| AR (1) | AR113893A1 (es) |
| AU (1) | AU2018372180B2 (es) |
| BR (1) | BR112020010215A2 (es) |
| CA (1) | CA3083022A1 (es) |
| CL (1) | CL2020001346A1 (es) |
| CO (1) | CO2020006206A2 (es) |
| CR (1) | CR20200216A (es) |
| EA (1) | EA202091279A1 (es) |
| ES (1) | ES2975319T3 (es) |
| IL (1) | IL274824A (es) |
| JO (1) | JOP20200128A1 (es) |
| MA (1) | MA51222A (es) |
| MX (1) | MX2020005332A (es) |
| PE (1) | PE20210157A1 (es) |
| SG (1) | SG11202004733WA (es) |
| TW (1) | TWI823878B (es) |
| UA (1) | UA126414C2 (es) |
| WO (1) | WO2019104086A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020005332A (es) | 2017-11-21 | 2021-01-08 | Denali Therapeutics Inc | Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion. |
| MA51339A (fr) | 2017-12-20 | 2020-10-28 | Denali Therapeutics Inc | Procédé de préparation de composés pyrimidinyl-4-aminopyrazole |
| WO2023174946A1 (en) | 2022-03-15 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Early and non-invasive method for assessing a subject's risk of having parkinson's disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
| CN103038230B (zh) | 2010-06-04 | 2016-05-25 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
| GB201015949D0 (en) | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| JP5986094B2 (ja) * | 2010-11-10 | 2016-09-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｌｒｒｋ２調節薬としてのピラゾールアミノピリミジン誘導体 |
| BR112014011219B1 (pt) | 2011-11-29 | 2022-08-23 | Genentech, Inc. | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
| PT2785711T (pt) | 2011-11-29 | 2016-09-30 | Hoffmann La Roche | Derivados de 2-(fenil ou pirid-3- il)aminopiridinacomo moduladores de lrrk2 quinase, para o tratamento da doença de parkinson |
| BR112014011850B1 (pt) | 2011-11-29 | 2022-01-11 | Genentech, Inc | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| MX363118B (es) | 2012-05-03 | 2019-03-11 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). |
| EP2844658B1 (en) | 2012-05-03 | 2019-03-20 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
| CN114315819A (zh) | 2016-06-16 | 2022-04-12 | 戴纳立制药公司 | 作为用于治疗神经退化性病症的lrrk2抑制剂的嘧啶-2-基氨基-1h-吡唑 |
| MX2020005332A (es) * | 2017-11-21 | 2021-01-08 | Denali Therapeutics Inc | Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion. |
-
2018
- 2018-11-20 MX MX2020005332A patent/MX2020005332A/es unknown
- 2018-11-20 WO PCT/US2018/062102 patent/WO2019104086A1/en active Application Filing
- 2018-11-20 ES ES18881859T patent/ES2975319T3/es active Active
- 2018-11-20 EP EP18881859.5A patent/EP3717473B1/en active Active
- 2018-11-20 JO JOP/2020/0128A patent/JOP20200128A1/ar unknown
- 2018-11-20 AR ARP180103389A patent/AR113893A1/es unknown
- 2018-11-20 BR BR112020010215-6A patent/BR112020010215A2/pt unknown
- 2018-11-20 US US16/197,037 patent/US10370361B2/en active Active
- 2018-11-20 SG SG11202004733WA patent/SG11202004733WA/en unknown
- 2018-11-20 KR KR1020207017598A patent/KR20200089713A/ko not_active Application Discontinuation
- 2018-11-20 UA UAA202003681A patent/UA126414C2/uk unknown
- 2018-11-20 CA CA3083022A patent/CA3083022A1/en active Pending
- 2018-11-20 PE PE2020000558A patent/PE20210157A1/es unknown
- 2018-11-20 CN CN201880081321.5A patent/CN111819174A/zh active Pending
- 2018-11-20 AU AU2018372180A patent/AU2018372180B2/en active Active
- 2018-11-20 CR CR20200216A patent/CR20200216A/es unknown
- 2018-11-20 TW TW107141257A patent/TWI823878B/zh active
- 2018-11-20 MA MA051222A patent/MA51222A/fr unknown
- 2018-11-20 EA EA202091279A patent/EA202091279A1/ru unknown
- 2018-11-20 JP JP2020545076A patent/JP7303821B2/ja active Active
-
2019
- 2019-06-20 US US16/447,713 patent/US10851088B2/en active Active
-
2020
- 2020-05-20 IL IL274824A patent/IL274824A/en unknown
- 2020-05-21 CL CL2020001346A patent/CL2020001346A1/es unknown
- 2020-05-21 CO CONC2020/0006206A patent/CO2020006206A2/es unknown
- 2020-11-27 US US17/105,870 patent/US11427571B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20200128A1 (ar) | 2020-05-21 |
| US20190194170A1 (en) | 2019-06-27 |
| TW201925190A (zh) | 2019-07-01 |
| JP7303821B2 (ja) | 2023-07-05 |
| BR112020010215A2 (pt) | 2020-11-03 |
| IL274824A (en) | 2020-07-30 |
| CN111819174A (zh) | 2020-10-23 |
| CO2020006206A2 (es) | 2020-08-10 |
| MA51222A (fr) | 2020-10-07 |
| UA126414C2 (uk) | 2022-09-28 |
| WO2019104086A1 (en) | 2019-05-31 |
| CL2020001346A1 (es) | 2020-11-20 |
| MX2020005332A (es) | 2021-01-08 |
| AU2018372180A1 (en) | 2020-06-18 |
| EA202091279A1 (ru) | 2020-08-19 |
| AR113893A1 (es) | 2020-06-24 |
| US20190315723A1 (en) | 2019-10-17 |
| TWI823878B (zh) | 2023-12-01 |
| AU2018372180B2 (en) | 2023-08-17 |
| CA3083022A1 (en) | 2019-05-31 |
| US11427571B2 (en) | 2022-08-30 |
| ES2975319T3 (es) | 2024-07-04 |
| SG11202004733WA (en) | 2020-06-29 |
| JP2021504450A (ja) | 2021-02-15 |
| EP3717473B1 (en) | 2024-01-10 |
| EP3717473A1 (en) | 2020-10-07 |
| EP3717473A4 (en) | 2021-07-07 |
| US10851088B2 (en) | 2020-12-01 |
| US10370361B2 (en) | 2019-08-06 |
| PE20210157A1 (es) | 2021-01-26 |
| KR20200089713A (ko) | 2020-07-27 |
| US20210087176A1 (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009764A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos. | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| WO2015132799A3 (en) | Heterocyclic compounds | |
| IL279101A (en) | Salts of spiafatrin are accepted in pharmacies | |
| MY199931A (en) | 3-substituted propionic acids as alpha v integrin inhibitors | |
| EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
| CR20200216A (es) | Polimorfos y formas sòlidas de un compuesto de pirimidinilamino-pirazol y mèdtodos de producciòn | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| MX2021008002A (es) | Sales nuevas y forma polimorfica del acido bempedoico. | |
| MX2022001410A (es) | Composiciones y metodos de uso de 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamid a. | |
| MA40059A (fr) | Inhibiteurs de la phosphatidylinositol 3-kinase | |
| MD3882250T2 (ro) | Tetrahidropiranil-amino-pirolopirimidinona pentru utilizare într-un procedeu de tratament al unei tulburări mediate de BTK | |
| WO2014192030A3 (en) | An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof | |
| EP4275707A3 (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| PH12016501903B1 (en) | Novel fused imidazobenzothiazole compounds | |
| MX2017003439A (es) | Formas cristalinas de inhibidores de tirosina cinasa y sus sales. | |
| HK1254731A1 (zh) | 用於醫學應用的3-(1，2，4-三唑並[4，3-a]吡啶-3-基乙炔基)-4-甲基-n-(4-((4-甲基哌嗪-1-基)甲基)-3-三氟甲基苯基)苯甲酰胺的新型結晶鹽形式 | |
| WO2016023028A3 (en) | G protein-coupled receptor kinase 2 inhibitors and methods for use of the same | |
| WO2015111085A3 (en) | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof | |
| MX2018007414A (es) | Formas solidas de compuestos de 5,6-dihidro-6-fenilbenzo[f¬]isoqui nolin-2-amina sustituidos. | |
| CL2017002180A1 (es) | Formas cristalinas de un compuesto de pirrolopiridina | |
| PH12017500323B1 (en) | P38 map kinase inhibiting indanyl urea compounds | |
| NZ748942A (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
| WO2015102017A8 (en) | Processes for the preparation of lorcaserin | |
| ZA202008062B (en) | Pharmaceutically acceptable salts of sepiapterin |